Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

China’s Prescription Drug Market to Reach $315 Billion in 2020

publication date: Aug 2, 2013
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
GlobalData, a London consultancy, projects China’s prescription drug market will expand at a 26% compound annual growth rate to $315 billion in 2020, up from $48 billion last year. One of the drivers is China’s investment in drug R&D. GlobalData also believes the growth will take place because of (not in spite of) price pressures being exerted by China’s government. By increasing affordability, less-expensive products will expand the market and more than make up for lower unit prices, says the company. More details....

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...